THE US Food and Drug Administration has requested that Endo Pharmaceuticals remove its opioid pain medication Opana ER (oxymorphone hydrochloride) from the market, on the basis that the benefits of the drug may no longer outweigh its risks.
The decision is based on post marketing data showing a significant shift in abuse patterns.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jun 17